Loading…
← CockpitCompetitor Analysis › 002332.SZ Zhejiang Xianju Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Zhejiang Xianju Pharmaceutical Co., Ltd. Class A002332.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Zhejiang manufacturer of steroid hormone APIs, a major Chinese supplier of corticosteroid and other hormone drug ingredients.

≈ A Chinese steroid-API supplierMomentum leader 88
Mkt cap
$1.28B
US dollars, full cap
Free float
74%
of shares outstanding
$/day
$22.1M
20-day average traded
Fwd P/E
17.7×
forward earnings
ROIC−WACC
+2.7 pp
WACC 6.4%
Hurdle
+1 pp
Req g minus delivered
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥8.59
1D-0.7%
1W-2.3%
1M-1.8%
3M-0.7%
6M-1.3%
YTD-4.7%
1Y-9.2%
ATR %1.9%
52w lowhigh14.5% off high

What Zhejiang Xianju Pharmaceutical does

Zhejiang manufacturer of steroid hormone APIs, a major Chinese supplier of corticosteroid and other hormone drug ingredients.

Sells steroid active ingredients in bulk to makers of finished tablets and injections, mostly generic drugmakers, priced by grade, with volumes and prices following hormone-drug demand and Chinese raw-material costs. Finished formulations are a smaller extension of the same chemistry.

In one line: A Chinese steroid-API supplier.

Products and services

  • Corticosteroid APIs
  • Other steroid hormone APIs
  • Finished steroid formulations

Customers

  • Generic-drug formulators worldwide

Where it sits in the supply chain

  • Pharmaceuticals
  • Active ingredients
  • Steroid hormone APIs

What could go right

  • Global generic steroid-drug demand

What could go wrong

  • API price competition
  • Environmental compliance costs

Moat: narrow (scale, regulatory licence). Large-scale steroid API production with multiple regulatory filings is costly for smaller rivals to match.

Headquarters: Xianju, Zhejiang, China · Employees: 3,209

Named competitors

Zhejiang Xianju Pharmaceutical at a glance

Size Zhejiang Xianju Pharmaceutical (002332.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.28B, the 1752nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.59 on 18 Nov 2026.

Performance Over six months the shares fell 1.3%, against -15.6% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 7.6% over the last twelve months (peer median +3.1%); the operating margin is 11.3% (peer median 0.8%).

Valuation It trades at 17.7× forward earnings against a peer median of 20.0× (5th cheapest of 11).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.7 points above its cost of capital (6.4% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026002332.SZ 99Peer median 85
Six months, rebased to 100: Zhejiang Xianju Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang Xianju Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.86BCN¥3.73BCN¥3.98BCN¥4.09BCN¥4.34B
Revenue growth—-6%-3%-6%—
Gross profitCN¥2.46BCN¥2.21BCN¥2.23BCN¥2.10BCN¥2.46B
EBITDAn/aCN¥640MCN¥839MCN¥816MCN¥864M
Net incomeCN¥465MCN¥450MCN¥397MCN¥563MCN¥749M
Free cash flowCN¥578MCN¥40.6MCN¥195MCN¥364MCN¥327M
Capital expenditureCN¥160MCN¥209MCN¥208MCN¥235MCN¥283M
Total debtCN¥218MCN¥378MCN¥81.3MCN¥446MCN¥426M

Quarterly statements and history in the cockpit →

Zhejiang Xianju Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%AMPH301263LBRX300204GHRSOCULINVAMNKD688293GPCRAVLN068760002099IDIA347850300181002332.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Xianju Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×200×400×AMPH301263300204688076MNKD000950688293300026002332.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Xianju Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%-20%0%20%AMPH688076INVA688293068760300026300181002332.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhejiang Xianju Pharmaceutical is the large dot.

Zhejiang Xianju Pharmaceutical competitors and peer comparison

Head to head with its named competitors (002332.SZ vs 300702.SZ vs 600488.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zhejiang Xianju Pharmaceutical 002332.SZ$1.28B-1%+8%11%17.7×-0.4%
Zhejiang Tianyu Pharmaceutical 300702.SZ$1.02B+1%+27%4%21.4×4.3%
Tianjin Tianyao Pharmaceuticals 600488.SS$718M-36%-12%3%n/a2.1%

How Zhejiang Xianju Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Xianju Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002332.SZPeer medianRank in peer set
1-month return-1.8%-5.1%6th highest of 20
6-month return-1.3%-15.6%6th highest of 20
Distance from 52-week high-14.5%-37.5%2nd highest of 20
Revenue growth (TTM)+7.6%+3.1%8th highest of 16
Operating margin11.3%0.8%6th highest of 16
Forward P/E17.7×20.0×5th cheapest of 11
Growth the price implies (Req g, 7 yrs)-0.4%3.9%2nd least demanding of 8
Growth delivered (Del g)-1.3%+18.1%2nd lowest of 8
Hurdle (Req g minus delivered)+1.0 pp-13.0 pp3rd most demanding of 8
ROIC minus cost of capital+2.7 pp-4.0 pp5th highest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%17.7×-0.4%-1.3%
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%9.1×2.5%+15.5%
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%60.7×n/an/a
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%522.3×n/an/a
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%11.9×3.4%+27.9%
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%n/an/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%9.5×-17.2%+3.9%
MannKind MNKDUnited States$1.31B+25%+32%-2%174.4×n/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%18.6×n/an/a
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%48.6×25.9%+23.1%
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%n/a10.2%+18.1%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%n/an/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%21.3×7.0%-5.3%
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%n/an/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%n/an/an/a
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%13.0×3.9%+22.8%

Questions

Who are Zhejiang Xianju Pharmaceutical's main competitors?
Named competitors: Zhejiang Tianyu Pharmaceutical (300702.SZ), Tianyao Pharmaceutical (600488.SS). The cockpit's measured peer set (industry) also includes Amphastar Pharmaceuticals (AMPH), Guangdong Taienkang Pharmaceutical (301263.SZ), LB Pharmaceuticals (LBRX), Staidson (Beijing) Biopharmaceuticals (300204.SZ), GH Research (GHRS), Sinopep-Allsino Bio Pharmaceutical (688076.SS).
Is Zhejiang Xianju Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 17.7× against a peer median of 20.0×, 5th cheapest of 11 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Zhejiang Xianju Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -1.3% against -15.6% for the median peer; over one year -9.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.